Cargando…
Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group
Medulloblastoma (MB) is the most common malignant central nervous system tumor of childhood, comprising a heterogenous group of tumors each with distinct biology, clinical behavior, and prognosis. Long-term survival remains unacceptable, and those who do survive face high late mortality risk, new ch...
Autores principales: | Cooney, Tab, Lindsay, Holly, Leary, Sarah, Wechsler-Reya, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755363/ https://www.ncbi.nlm.nih.gov/pubmed/36516489 http://dx.doi.org/10.1016/j.neo.2022.100861 |
Ejemplares similares
-
Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)
por: Nicolaides, Theodore, et al.
Publicado: (2020) -
LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials
por: von Reppert, Marc, et al.
Publicado: (2022) -
OUTC-08. IMPLEMENTING SOCIAL DETERMINANT OF HEALTH DATA COLLECTION FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT NEURO-ONCOLOGY PATIENTS IN THE CLINICAL TRIAL CONSORTIA SETTING: PROGRESS AND CHALLENGES
por: Puthenpura, Vidya, et al.
Publicado: (2023) -
MEDB-47. CD4+ T cells restrict medulloblastoma growth and dissemination
por: Eisemann, Tanja, et al.
Publicado: (2022) -
Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma
por: Eisemann, Tanja, et al.
Publicado: (2022)